Idorsia Reports MAA Submission of Aprocitentan to EMA for the Treatment of Resistant Hypertension
Shots:
- The company has submitted a MAA to the EMA for aprocitentan (dual endothelin receptor antagonist) for the treatment of patients with resistant hypertension
- The MAA was based on the results from a comprehensive clinical and non-clinical development program incl. the P-III registration study (PRECISION) consisted of three sequential parts (Part 1/2/3) evaluating Aprocitentan in 730 patients at hospitals or research centers in EU, North America, Asia, and Australia
- The results showed that the patients treated with aprocitentan achieved a significant and clinical reduction in blood pressure which was maintained for ~48wks. when added to combination background antihypertensive therapy. The therapy was well tolerated with no major safety concerns
Ref: GlobeNewswire | Image: Idorsia
Related News:- Simcere Entered into an Exclusive License Agreement with Idorsia for Daridorexant in China
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
